Ophthotech Corp (OPHT) Tops Q4 EPS by 29c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Ophthotech Reports Fourth Quarter and Full Year 2017 Financial and Operating Results
February 27, 2018 6:33 AM EST(Conference Call and Webcast Today, February 27, 2018, at 8:00 a.m. ET)
- Ophthotech Targets Novel Gene Therapy Technology for Orphan and Age-Related Retinal Diseases -
- Complement C5 Inhibitor, Zimura®, on Track with Four Ongoing Ophthalmic Clinical Programs -
NEW YORK--(BUSINESS WIRE)-- Ophthotech Corporation (Nasdaq: OPHT) today announced financial and operating results for the fourth quarter and full year ended December 31, 2017 and provided a business update.
The Company also announced today that it has initiated an... More
